Post–cardiac transplant survival after support with a continuous-flow left ventricular assist device: Impact of duration of left ventricular assist device support and other variables  by John, Ranjit et al.
T
X
Cardiothoracic Transplantation John et alPost–cardiac transplant survival after support with a continuous-flow
left ventricular assist device: Impact of duration of left ventricular
assist device support and other variablesRanjit John, MD,a Francis D. Pagani, MD,b Yoshifumi Naka, MD,c Andrew Boyle, MD,a
John V. Conte, MD,d Stuart D. Russell, MD,d Charles T. Klodell, MD,e Carmelo A. Milano, MD,f
Joseph Rogers, MD,f David J. Farrar, PhD,g and O. Howard Frazier, MDhFrom th
Minn
York,
Gaine
Calif;
Disclosu
fees a
Read at
Surge
Receive
public
Address
of Mi
0022-52
Copyrig
doi:10.1
174Objective: Although left ventricular assist devices (LVADs) are associated with excellent outcomes in patients
with end-stage heart failure, there are conflicting reports on posttransplant survival in these patients. Furthermore,
prior studies with pulsatile LVADs have shown that transplantation, either early (<6 weeks) or late (>6 months)
after LVAD implantation, adversely affected post–cardiac transplant survival. We sought to determine factors
related to posttransplant survival in patients supported with continuous-flow LVADs.
Methods: The HeartMate II LVAD (Thoratec Corporation, Pleasanton, Calif) was implanted in 468 patients as
a bridge to transplant at 36 centers in a multicenter trial. Patients who underwent transplantation after support were
stratified by demographics: gender, age, etiology, body mass index, duration of device support, and by adverse
events during support. The median age was 54 years (range 18–73 years); 43% had ischemic etiology, and 18%
were women. Survival was determined at the specific intervals of 30 days and 1 year after transplantation.
Results:Of 468 patients, 250 (53%) underwent cardiac transplant after amedian duration of LVADsupport of 151
days (longest: 3.2 years), 106 (23%) died, 12 (2.6%) recovered ventricular function and the device was removed,
and 100 (21%) were still receiving LVAD support. The overall 30-day and 1-year posttransplant survivals were
97% and 87%. There were no significant differences in survival based on demographic factors or LVAD duration
of less than 30 days, 30 to 90 days, 90 to 180 days, and more than 180 days. Patients requiring more than 2 units of
packed red blood cells in 24 hours during LVAD support had a statistically significant decreased 1-year survival
(82% vs 94%) when compared with patients who did not require more than 2 units of packed red blood cells in 24
hours during LVAD support (P¼ .03). There was a trend for slightly lower survival at 1 year in patients with per-
cutaneous lead infections during LVAD support versus no infection (75% vs 89%; P ¼ .07).
Conclusions: Post–cardiac transplant survival in patients supported with continuous-flow devices such as the
HeartMate II LVAD is equivalent to that with conventional transplantation. Furthermore, posttransplant survival
is not influenced by the duration of LVAD support. The improved durability and reduced short- and long-term
morbidity associated with the HeartMate II LVAD has reduced the need for urgent cardiac transplantation, which
may have adversely influenced survival in the pulsatile LVAD era. This information may have significant impli-
cations for changing the current United Network for Organ Sharing criteria regarding listing of heart transplant
candidates. (J Thorac Cardiovasc Surg 2010;140:174-81)Heart transplantation is an established treatment modality for
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The Journal of Thoracic and Cardiovascular Surgwith a left ventricular assist device (LVAD), with a smaller
proportion receiving LVADs as destination therapy.2 Most
patients who have undergone LVAD placement as a bridge
to transplant (BTT) in the United States have been supported
by pulsatile, volume-displacement devices such as the Heart-
Mate XVE (Thoratec Corporation, Pleasanton, Calif).3,4
These devices provide excellent hemodynamic support and
improve patient survivals, but they do have significant
constraints, including the need for extensive surgical
dissection, requirement for the patient to have a large body
habitus, need for a large-diameter percutaneous lead, and au-
dible pump operation. Importantly, long-term mechanical
durability is limited, frequently resulting in reoperations for
device exchange. The newHeartMate II LVAD,which incor-
porates continuous-flow rotary pump technology, represents
the next generation of devices. Continuous-flow rotaryery c July 2010
Abbreviations and Acronyms
BTT ¼ bridge to transplant
FDA ¼ Food and Drug Administration
LVAD ¼ left ventricular assist device
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Xpumps are thought to have enhanced durability and provide
improved quality of life for extended periods of support. A
major advantage of these new pumps is their small size,
thereby extending therapy to underserved patient popula-
tions including women and even some children.
Although results with LVADs have consistently improved
over time, several questions remain with regard to patient
management and optimal timing of cardiac transplantation
after initiation of LVAD support.5,6 The decision to
proceed with heart transplantation after initiation of LVAD
support is guided partly by variables not in full control of
the transplant team, such as donor availability, United
Network for Organ Sharing (UNOS) policy for listing, and
patient-related variables such as blood group and body
size. Ultimately, the decision to proceed with active listing
lies with the transplant team, as is the decision to either accept
or refuse a donor heart for the potential recipient. In recent
years, significant UNOS policy changes affecting LVAD
BTT candidates have occurred on the basis of outcomes
data in patients supported with pulsatile devices.7 It is possi-
ble that additional changes can occur on the basis of the post-
transplant survival outcomes in patients supported with the
newer generation continuous-flow rotary devices.
Furthermore, although results using LVADs as BTT are
similar to those in patients undergoing transplantationwithout
LVAD support, there have been conflicting reports on the im-
pact of LVADs on posttransplant survival.8-13 Concerns have
also been raised regarding the negative effects of return to full
pulsatility after cardiac transplantation in patients supported
with continuous-flow devices.14 Continuous-flow devices
have rapidly become the standard of care when used as
a BTT with excellent outcomes reported.15 However, limited
data have been reported on the posttransplant survival in pa-
tients supported by continuous-flow devices. The objective
of this study was to evaluate the influence of patient demo-
graphics, duration of LVAD support, and adverse events dur-
ing LVAD support on posttransplant survival in patients
supported by the HeartMate II LVAD.
The HeartMate II LVAD, a continuous-flow rotary pump
with an axial blood flow path design, has recently concluded
a Food and Drug Administration (FDA)–approved pivotal
trial in 133 patients designed to evaluate outcomes at 6
months.15 Since that first report, 335 additional patients
have undergone implantation of the HeartMate II LVADThe Journal of Thoracic and Caas of April 2008 through a continued-access protocol ap-
proved by the FDA, and 250 have received transplants.
We thereby report on the posttransplant survival results in
patients who have undergone heart transplantation from
this large observational clinical study using the HeartMate
II LVAD as a BTT.
PATIENTS AND METHODS
Study Organization
Patients were enrolled in the study conducted at 35 centers in the United
States and Canada between March 2005 and April 2008. The study was su-
pervised by the sponsor (Thoratec Corporation). Coordinators at each site
collected all study data, which were then forwarded to the data analysis cen-
ter of the sponsor. The academic authors vouch for the completeness and ac-
curacy of the data and the analyses. A data and safety monitoring board,
consisting of 4 independent physicians and 1 biostatician who were not in-
vestigators in the study, met routinely to review study compliance, adverse
events, quality of life, and outcomes of patients. A clinical events committee
of 4 independent physicians reviewed, classified, and adjudicated the causes
of death and all adverse events. The studywas conducted in compliancewith
FDA regulations for Good Clinical Practices. The protocol was approved by
the FDA and the institutional review board at each participating center.
Study Subjects
Patients with end-stage heart failure and listed for heart transplantation at
each center were eligible for study enrollment. Detailed inclusion and exclu-
sion criteria have been previously presented.15 Patients were required to
have New York Heart Association class IV heart failure symptoms and to
be ill enough to have high priority for transplantation (UNOS status 1A
or 1B). Exclusion criteria included severe renal, pulmonary, or hepatic dys-
function, active uncontrolled infection, a mechanical aortic valve, aortic in-
sufficiency, an aortic aneurysm, other mechanical circulatory support
(except an intra-aortic balloon pump), and technical obstacles thought by
the investigator to pose an increased surgical risk. All participating patients
provided written informed consent.
Baseline Assessment
Baseline data were collected on demographics, health history, NewYork
Heart Association functional class, blood chemistries, hematology data,
neurologic status, and concomitant medications.
HeartMate II LVAD
The pump used in this study was the HeartMate II LVAD (Thoratec Cor-
poration), which is a continuous-flow device consisting of an internal axial
flow blood pump with a percutaneous lead that connects the pump to an ex-
ternal system driver and power source, which has been previous de-
scribed.15 The pump contains an internal rotor with helical blades that
curve around a central shaft. When the rotor spins on its axis, kinetic energy
is imparted to the blood, which is drawn continuously from the left ventric-
ular apex through the pump and into the ascending aorta. The pump has an
implant volume of 63 mL and generates up to 10 L/min of flow at a mean
pressure of 100 mm Hg.
Surgical Implantation
Surgical implantation of the HeartMate II LVAS was conducted accord-
ing to the HeartMate II LVAS Instructions for Use. Postoperative treatment
included close monitoring of the patient’s anticoagulation regimen.
Postimplant Follow-up
After device implantation, a standardized antithrombotic regimen was
implemented with initiation of heparin followed by transition to warfarinrdiovascular Surgery c Volume 140, Number 1 175
TABLE 1. Baseline characteristics of the 250 LVAD patients who
underwent heart transplantation
Characteristic
Mean ± SD or
no. (%) (n ¼ 250)
Age (y) 51  13
Male (%) 204 (82%)
Body mass index (kg/m2) 27  5.6
Body surface area (m2) 2.0  0.3
Ischemic etiology of heart failure (%) 107 (43%)
Left ventricular ejection fraction (%) 16.1  6.5
Arterial blood pressure (mm Hg)
Systolic 98.2  15.4
Diastolic 62.3  12.1
Pulmonary capillary wedge pressure (mm Hg) 25.4  8.2
Cardiac index (L $ min1 $ m2) 2.1  0.7
Heart rate (beats/min) 92  18
Pulmonary artery pressure (mm Hg)
Systolic 51.5  13.2
Diastolic 26.7  8.0
Mean 35.8  9.0
Pulmonary vascular resistance (Wood units) 2.8  1.4
Central venous pressure (mm Hg) 12  6
NYHA class IV (221/250)
Serum sodium (mmol/L) 133.3  5.2
Serum albumin (g/dL) 3.6  1.8
Pre-albumin (mg/dL) 18.5  7.7
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antiarrhythmic, and heart failure therapy, was performed according to each
investigator’s preference and usual practice.
Posttransplant Follow-up
After transplant, patients were followed up by centers based on each cen-
ter’s own routine posttransplant follow-up schedule. Each center completed
a form to document 1-month and 1-year posttransplant survival. This study
did not evaluate posttransplant complications such as rejection, infections,
or readmissions.
Survival after transplantation was determined at 2 specific time points:
30 days and 1 year. Patients were stratified by demographic factors (age,
gender, body mass index, and etiology of heart failure), the presence of ad-
verse events during LVAD support (bleeding requiring more than 2 units of
packed red blood cells (PRBCs) per any 24-hour period after LVAD im-
plant, bleeding requiring reoperation, any infection adverse event during
support, infection at the percutaneous lead exit site or pump pocket, renal
dysfunction (last serum creatinine value> 1.7 mg/dL during support or
blood urea nitrogen value>30 mg/dL), and hepatic dysfunction (last ala-
nine aminotransferaase value>40 IU during support).
Survival after transplantation was also comparedwith the survival for pa-
tients continuing on LVAD support, starting at 6 months of support and con-
tinuing through 18 months of support (censored for transplantation).
Statistical Analysis
Differences between groups were determined with Fisher’s exact test
or the Pearson c2 test where appropriate. All statistical comparisons are
2-sided.Cholesterol (mg/dL) 129  41
Serum creatinine (mg/dL) 1.4  0.5
Blood urea nitrogen (mg/dL) 29.8  16.7
ALT (IU/L) 106  278
AST (IU/L) 91  223
Total bilirubin (mg/dL) 1.3  0.8
LDH (mg/dL) 567  1538
Hematocrit (%) 34.8  5.7
White blood count (31000/mL) 8.8  3.3
Platelets (1000/mL) 225  87
International normalized ratio 1.3  0.3
Concomitant medications
Intravenous inotrope agents 228 (91%)
Intolerant to inotropes owing to arrhythmias 22 (9%)
Biventricular pacemaker 119 (48%)
ICD 192 (77%)
IABP 115 (46%)
Mechanical ventilation 18 (7%)
LVAD, Left ventricular assist device; SD, standard deviation; NYHA, New York Heart
Association; ALT, serum alanine aminotransaminase; AST, serum aspartate aminotran-
saminase; LDH, lactate dehydrogenase; ICD, implantable cardioverter–defibrillator;
IABP, intra-aortic balloon pump.RESULTS
Study Patients
A total of 468 patients who met study-entry criteria were
enrolled into the study as of April 2008 and underwent im-
plantation of the continuous-flow pump as a BTT. Of 468
patients, 250 (53%) underwent cardiac transplantation and
are the focus of this report. In addition, 106 (23%) died,
12 (2.6%) recovered ventricular function and the device
was removed, and 100 (21%) were still receiving LVAD
support. Of the transplanted patients, 229 patients have com-
pleted a 30-day follow-up and 190 patients have completed
a 1-year follow-up.
Baseline characteristics of the patients who underwent
transplantation are shown inTable 1. Themajority of subjects
were men with a median age of 54 years. The most frequent
etiology of the heart failure was nonischemic cardiomyopa-
thy. All patients had symptoms of advanced heart failure de-
spite optimal medical management with oral medications.
Themajority of patients in the studywere receiving inotropic
therapy and those not receiving inotropic therapy at the time
of LVAD implantation were intolerant to inotropic therapy
owing to ventricular arrhythmias. Forty-six percent of pa-
tients were receiving concomitant support with an intra-
aortic balloon pump. A significant proportion had previously
received biventricular pacing therapy. The majority of
patients were listed at UNOS status 1A. Preoperative hemo-
dynamic and laboratory assessment were consistent with
a group of patients with advanced heart failure (Table 1).176 The Journal of Thoracic and Cardiovascular SurgOutcomes
Posttransplant survival. Of 468 patients, 250 (53%) un-
derwent cardiac transplantation after a median duration of
LVAD support of 151 days (longest: 3.2 years). Of the pa-
tients undergoing transplantation, 229 patients have com-
pleted a 30-day follow-up and 190 have completed a 1-year
follow-up.
Overall 30-day and 1-year survivals are 97% and 87%,
respectively. The 1-year survival was 88% for men andery c July 2010
TABLE 2. Posttransplant survival versus patient demographics
Demographic LVAD duration Survival at 30 days P value Survival at 1 year P value
Overall All 151 (3.2 y) 222/229 (97%) 165/190 (87%)
Etiology Ischemic 152 (1.7 y) 100/102 (98%) .47 74/85 (87%) 1.00
Nonischemic 143 (3.2 y) 122/127 (96%) 91/105 (87%)
Gender Male 145 (3.2 y) 182/187 (97%) .36 136/155 (88%) .41
Female 159 (1.7 y) 38/40 (95%) 28/34 (82%)
Age (y) <50 131 (3.2 y) 82/85 (97%) .92 66/75 (88%) .93
50–59 172 (3.2 y) 79/81 (98%) 56/65 (86%)
60 151 (1.8 y) 61/63 (97%) 43/50 (86%)
Body mass index <20 131 (1.4 y) 19/21 (91%) .10 16/19 (84%) .75
20–29 136 (3.2 y) 136/138 (99%) 99/112 (88%)
30 173 (3.2 y) 66/69 (96%) 50/59 (85%)
LVAD, Left ventricular assist device.
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ferences in 30-day and 1-year posttransplant survivals
among these patients when stratified by demographics in-
cluding age, gender, etiology of heart failure, and body
mass index (Table 2).
The patients undergoing transplantation were also strati-
fied into 4 groups on the basis of duration of LVAD support
ranging from less than 30 days to more than 180 days. There
were no significant differences in either 30-day or 1-year
posttransplant survivals among the 4 groups (Table 3). There
was also no significant difference in either 30-day or 1-year
posttransplant survivals when patients supported for more
than 180 days were subdivided into 180 to 365 days and
more than 365 days (Table 4).
Last, posttransplant survivalwas also stratified on the basis
of the occurrence of adverse events during LVAD support as
well as end-organ function before transplantation (Table 5).
Patients requiring more than 2 units of PRBCs in 24 hours
during LVAD support had a statistically significantly de-
creased 1-year survival (82% vs 94%) when compared
with patients who did not requiremore than 2 units of PRBCs
in 24 hours during LVAD support (P ¼ .03). There was
a trend for slightly lower survival at 1 year (75%) in 28 pa-
tients with percutaneous lead infections during LVAD sup-
port versus no infection (89%) (P ¼ .07) and in 15 patients
in whom the last creatinine level before transplant was
more than 1.7 mg/dL (73% vs 88%) when compared with
patients in whom the creatinine level before transplant was
less than 1.7mg/dL (P¼ .12). However, there were no statis-
tically significant differences in 30-day or 1-year posttrans-
plant survivals among the other groups, as shown in Table 5.TABLE 3. Posttransplant survival versus LVAD duration
LVAD duration Median days (maximum) Survival at 3
<30 days 18 (28) 17/17 (100
30–89 days 58 (89) 62/62 (100
90–179 days 135 (179) 57/60 (95%
180 days 258 (3.2 yr) 86/90 (96%
LVAD, Left ventricular assist device.
The Journal of Thoracic and CaPosttransplant survival versus survival after 6 months
of LVAD support. The 30-day and 1-year survivals for pa-
tients continuing on LVAD support (starting from 6 months
of support, through 18 months, and censored for transplan-
tation) were 98% and 87%. This was not statistically signif-
icantly different from the 30-day and 1-year posttransplant
survivals of 97% and 87%. We used a starting point of 6
months for this analysis inasmuch as the median duration
for timing of transplant on LVAD support was 151 days.DISCUSSION
The discrepancy between the limited availability of donor
hearts and the ever-increasing number of patients with heart
failure has led to the increasing use of LVADs as a BTT.
The use ofmechanical circulatory support asBTThas evolved
to become the standard of care in most cardiac transplant
programs. However, several studies report that BTTwith ven-
tricular assist devices may reduce posttransplant survival.8-13
The findings from this study support and validate the use of
the HeartMate II as BTT. These acceptable posttransplant
survival data are closely linked to the outcomes during
HeartMate II LVAD support that have been previously
published.15
Patients with LVAD support who received more than 2
units of PRBCs in 24 hours during LVAD support had a sig-
nificantly reduced 1-year posttransplant survival. The rela-
tionship between blood transfusions and increased
morbidity and mortality in patients undergoing cardiac sur-
gery is widely known.16 Whether this is because of the rela-
tionship between the use of blood products and an increased0 days P value Survival at 1 year P value
%) .28 16/17 (94%) .18
%) 55/59 (93%)
) 46/55 (84%)
) 48/59 (81%)
rdiovascular Surgery c Volume 140, Number 1 177
TABLE 4. Posttransplant survival versus LVAD duration
LVAD duration Median days (maximum) Survival at 30 days P value Survival at 1 year P value
<30 days 18 (28) 17/17 (100%) .22 16/17 (94%) .28
30–89 days 58 (89) 62/62 (100%) 55/59 (93%)
90–179 days 135 (179) 57/60 (95%) 46/55 (84%)
180–365 days 227 (363) 64/68 (94%) 37/45 (82%)
>365 days 507 (3.2 yr) 22/22 (100%) 11/14 (79%)
LVAD, Left ventricular assist device.
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from this study, although these relationships have been
widely characterized, as shown in the next section.
Although the development of circulating antibodies,
termed ‘‘sensitization,’’ does not affect early perioperative
LVAD-related morbidity and mortality, it has significant ad-
verse effects, especially on posttransplant outcomes.17 Prior
experience with pulsatile devices has been associated with
a greater than 50% incidence of sensitization from some
studies.16 The increased use of blood products during
LVAD placement is reported to be a significant risk factor
for the development of sensitization.18 The decreased post-
transplant survival in LVAD patients in this study who re-
ceived more than 2 units of PRBCs during LVAD support
may be related to the adverse impact of sensitization. Inter-
estingly, LVAD-related infections may also contribute to the
development of sensitization. As a result of these circulating
antibodies, LVAD recipients have a high likelihood ofTABLE 5. Posttransplant survival versus adverse events during LVAD sup
Adverse event LVAD duration
Any infection
during LVAD support
No 120 (3.2 y)
Yes 192 (2.1 y)
Percutaneous lead
infection during LVAD
support
No 126 (3.2 y)
Yes 253 (2.1 y)
Reoperation for bleeding
during LVAD support
No 149 (3.2 y)
Yes 152 (3.2 y)
Bleeding requiring>2 U
PRBC/24 h during LVAD
support
No 130 (2.1 y)
Yes 162 (3.2 y)
Last creatinine
value during LVAD support
<1.7 mg/dL (1.1  0.1) 143 (3.2 y)
1.7 mg/dL (2.2  0.5) 194 (1.5 y)
Last blood
urea nitrogen value
during LVAD support
<30 mg/dL (17  5) 143 (3.2 y)
30 mg/dL (46  19) 178 (1.3 y)
Last ALT value
during LVAD support
<40 IU (24  8) 157 (3.2 y)
40 IU (62  38) 120 (1.8 y)
LVAD, Left ventricular assist device; PRBC, packed red blood cell; ALT, serum alanine am
178 The Journal of Thoracic and Cardiovascular Surgrepeated donor-specific T cell cross-match reactivity, with
the consequence of increased waiting time to transplanta-
tion. Thus, it is may not be uncommon for sensitized patients
to receive a suboptimal donor inasmuch as the opportunity to
obtain an immunologic compatible donor is low. The trend
toward slightly increased mortality in patients supported
for more than 12 months (although not significant) could
be related to sensitization, because sensitized patients tend
to wait longer for an immunologically compatible donor.
Thus, although we did not measure the level of preformed
antibodies in the patients receiving a HeartMate II device
in this study, prior studies do point to the possibility of sen-
sitization (from possible blood use and infections) on de-
creased posttransplant survival.19
The incidence of LVAD-related infection in the multicen-
ter study was low, although the incidence increased after 30
days of support.15,20 The impact of infections during LVAD
support on posttransplant outcomes is also controversial.21 Itport
Survival at 30 days P value Survival at 1 year P value
132/135 (98%) .45 102/115 (89%) .38
90/94 (96%) 63/75 (84%)
185/189 (98%) .10 144/162 (89%) .07
37/40 (93%) 21/28 (75%)
180/184 (98%) .14 133/152 (88%) .60
42/45 (93%) 32/38 (84%)
88/90 (98%) .71 74/79 (94%) .03
134/139 (96%) 91/111 (82%)
202/209 (97%) 1.00 154/175 (88%) .12
20/20 (100%) 11/15 (73%)
200/206 (97%) .53 151/172 (88%) .27
22/23 (96%) 14/18 (78%)
171/177 (97%) 1.00 124/142 (87%) .81
51/52 (98%) 41/48 (85%)
inotransaminase; AST, serum aspartate aminotransaminase.
ery c July 2010
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driveline infection with increased duration of support, with
one study reporting an incidence of 94% at 1 year of support
with pulsatile devices.22 Although the overall incidence of
driveline infections with the HeartMate II LVAD was
low,15 in this study, there was a trend toward poorer survival
(P¼ .07) in patients undergoing transplantation with a drive-
line infection. There was also a trend toward slightly reduced
survival (not significant) in patients supported for more than
12 months (11/14, 79% 1-year survival). Of the 14 patients
in this group, there were 8 with driveline infections, includ-
ing all 3 patients who died and 5 of the 11 who survived.
Patients with LVAD-related infections are known to wait
longer for a heart transplant, presumably delayed by the
need for often prolonged antibiotic therapy. Although signif-
icant progress has been made with LVAD-related infections,
continued research is critical to further reduce and even
eliminate driveline-related infections.
The development of right ventricular failure after LVAD
implantation is also associated not only with reduced suc-
cess of BTT but also with increased posttransplant mortality.
The multicenter pivotal study has reported a significantly re-
duced incidence of right ventricular failure after HeartMate
II implantation.15,23 The development of right ventricular
failure after LVAD implantation is sometimes associated
with an increased urgency for transplantation and thereby
a tendency to use suboptimal donors for transplant. The
lower incidence of right ventricular failure seen with the
HeartMate II LVAD might also have contributed to the
improved posttransplant survival.
Durability and reliability of LVAD design is perhaps one
of the most significant features for extended use of mechan-
ical circulatory support devices. Previous studies have dem-
onstrated limited durability and reliability of the pulsatile
HeartMate XVE LVAD, with nearly 50% of patients requir-
ing device exchange owing to infection or mechanical mal-
function at 18 months.24 Very few device replacements were
required for device thrombosis and infection in the Heart-
Mate II pivotal study. No mechanical failures of the device
pumping mechanism were observed.15 The absence of me-
chanical failures of the pumping mechanism is significant
and has not been previously observed in trials evaluating
older technology.15 The remarkable durability of the Heart-
Mate LVAD can allow for improved donor selection as op-
posed to the pulsatile pump era, in which decreasing
durability beyond the 1-year mark increased the urgency
for transplantation and a subsequent potential for suboptimal
donor selection. The 87% 1-year survival for patients re-
ceiving LVAD support (starting from 6 months of support),
which is similar to the 1-year posttransplant survival, sup-
ports that at least in the short-term follow-up, optimizing
donor selection is feasible with the HeartMate II LVAD.
Our data may have significant implications for changing
the current UNOS criteria regarding listing of LVAD-The Journal of Thoracic and Cabridged heart transplant candidates. In the previous Heart-
Mate XVE era, changes in UNOS policy significantly
affected LVAD-bridged candidates. Although further data
with longer-term follow-up is essential to make definitive
recommendations, our data might suggest whether patients
in stable condition with a HeartMate II LVAD should be
listed as a UNOS status IA in the absence of any LVAD-
related complications.7,25
More relevant to this study is a recent report that a pro-
longed duration of support with continuous-flow devices
may be associated with greater hemodynamic compromise,
as demonstrated by the need for higher dose requirements
and increased duration of pressor support after restoration
of pulsatility at the time of transplantation.14 Although it
should be noted that the later study showed no differences
in early posttransplant mortality when compared with pa-
tients receiving pulsatile devices, there are studies that
have noted differences in vascular tone and endothelial func-
tion in patients supported with continuous-flow devices.26
Limitations
A number of limitations are important in the interpretation
of data from this present study. The study was nonrandom-
ized with no real risk-adjusted group for direct comparison,
although comparing the efficacy of LVADs as a BTT ther-
apy with a medical control group would be considered
unethical. Also, some important variables that were not ex-
amined in this study but could potentially influence trans-
plant survival include HLA sensitization and pulmonary
vascular resistance. There are also no data evaluated on post-
transplant morbidity such as rejections, infections, and post-
transplant length of stay and hospital readmissions. This
study also had a limited 1-year posttransplant follow-up. Im-
portantly, the causes of posttransplant death were unknown;
this information could have shed light on the trend toward
increased mortality in patients supported with the HeartMate
II LVAD with percutaneous lead infections that underwent
transplantation.
In summary, the HeartMate II LVAD as a BTT provides
1-year posttransplant survival that appears similar to that of
conventional transplantation. Importantly, no differences in
posttransplant survival were found when patients were strat-
ified on the basis of duration of LVAD support as well as
other demographic variables and post-LVAD adverse
events. However, the increased use of blood transfusions
during LVAD support significantly reduced transplant sur-
vival with a trend toward reduced posttransplant survival
in patients with driveline infections. Further evaluation is
necessary to understand the association with increased post-
transplant mortality in the LVAD patients experiencing
these later adverse events. Thus, there is no reason to support
any hypothesis that the reduced pulsatility associated with
continuous-flow devices such as the HeartMate II has any
adverse impact on posttransplant survival. In conclusion,rdiovascular Surgery c Volume 140, Number 1 179
Cardiothoracic Transplantation John et al
T
Xduration of support with the HeartMate II LVAD does not
affect posttransplant survival, unlike the earlier experience
with patients supported with pulsatile devices.
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Dr James K. Kirklin (Birmingham, Ala). I have no financial
disclosures to make.
I congratulate the authors on a very nice analysis of the Heart-
Mate II experience as BTT therapy. This reflects the changing land-
scape that is occurring in mechanical support as the vast majority of
devices now implanted are these smaller rotary pumps.
My first question relates to driveline infection. As we know, the
major Achilles’ heel of this pump and others like it is the ongoing
low risk, which continues to be constant over time, of driveline in-
fections developing. You showed some potentially important infor-
mation in that even though the P value was .07, the 75% 1-year
survival associated with patients who had driveline infections
was perhaps important. In view of that, do you have plans to go
back and specifically review the causes of death in that cohort of
patients so that we can better clarify this issue?
Dr John. That is an important question. Yes, we do plan to.
Luckily it is a small number of patients, about 14 or 15, and we
should be able to track that down. It would be important to identify
whether these posttransplant deaths were specifically related to in-
fection and, even more importantly, whether the microbiologic
studies performed in these patients who may have died of sepsis
showed that the bacteria identified were similar to the original bac-
teria isolated at the time of driveline infections.
I think the take-home message is that patients with driveline in-
fections should be adequately treated with long-term intravenous
antibiotic therapy before transplantation, and many of these pa-
tients in our experience need maintenance therapy with oral antibi-
otics until the time of transplantation, even though their driveline
infection seems to be eradicated.
Dr Kirklin. My second and final question relates to duration of
LVAD support. Your data indicate and you conclude that the dura-
tion of LVAD support no longer has any influence on posttrans-
plant survival, and this obviously has important implications. I
am still not totally comfortable with your analysis and yourery c July 2010
John et al Cardiothoracic Transplantationconclusions in that there was a small decrease, although nonsignif-
icant, in survival for those patients who were supported greater than
6 months. Furthermore, most of these were basically univariate
analyses.
Do you think it would be advisable to now go back and do
a more detailed multivariable analysis looking at duration of sup-
port as a continuous variable and at possible interactions with other
risk factors before concluding securely that extended LVAD sup-
port has no impact on intermediate-term or long-term survival after
transplant? To follow up on that, on the basis of your analysis,
would you currently recommend that the priority status for LVADs
in obtaining donor hearts be eliminated because of your conclusion
that there is no impact on duration and survival?
Dr John. Thank you. Those are very important comments. With
increasing duration of LVAD support, 2 other variables occur with
increased frequency in patients supported for longer than 6 months.
First, there is an increasing incidence of driveline infections the lon-
ger patients are receiving LVAD support. Second, patients who are
waiting a long time on LVAD support may be waiting because they
are sensitized. The increased incidence of both of these variables
may account for the slight decrease in posttransplant survival
when patients are on LVAD support for longer durations. It is im-
portant, therefore, to do a multivariate analysis to identify the clin-
ically significant variables—infection, sensitization, increased
duration, or a combination of these risk factors.
Currently, patients on LVAD support are usually assigned 1B
status on the UNOS list and then get upgraded to a 1A status for
a 1-month period after LVAD implantation. Most centers choose
the timing of the upgrade to a 1A status around the 2- to 6-month
mark, depending on blood group, regional based waiting times,
as well as clinical patient-related variables. As reported in this
study, the median duration of support for LVAD patients beforeThe Journal of Thoracic and Catransplantation is about 150 days. This might suggest that there
may be support for removal of the 1A status for a stable LVAD pa-
tient and only allow the special status of 1A for LVAD patients who
are experiencing an adverse complication such as infection, severe
arrhythmias, or sensitization. I think upgrading to a 1A status for
a stable LVAD patient at home who is doing clinically well comes
into question, in light of the increasing durability of currently avail-
able LVADs.
Dr Kirklin. Very nice analysis. Thank you.
Dr Stephen J. Lahey (Brooklyn, NY). I was very interested to
see that one of your adverse risk factors was blood transfusions.
This is a very interesting topic, not just in your particular area
but in all of cardiac surgery. Multiple groups, such as the Northern
New England Consortium, have reported that blood transfusions
are a very, very bad thing and do predict mortality. Perhaps it would
it be helpful if we had some idea of the triggers for transfusion. You
have 33 centers. There may be some centers that will transfuse at
a hematocrit value of 24% or others at a hematocrit value of
28%. This fact, in and of itself, can be a confounder as far as using
‘‘blood transfusion’’ as an adverse risk predictor.
Dr John. I agree. Our general policy at our center is to delay
blood transfusions for as long as possible, even up to a hemoglobin
value of 8 g, because these patients could get sensitized with the
next unit of blood, but that information is important. Unfortunately,
that trigger is not going to be obtained because of the number of
centers and variable triggers for each center. But that is important
information, I agree.
Dr David H. Adams (New York, NY). I do not know whether
you know the age of your transfusion, but a paper published last
year from Cleveland showed the age of blood products also nega-
tively affected survival, and it may be something worth looking at
as well.rdiovascular Surgery c Volume 140, Number 1 181
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